Destiny Pharma is a clinical stage, biotechnology company focused on the development of novel medicines that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life‑threatening infections caused by antibiotic resistant bacteria, often referred to as superbugs. Infections caused by antibiotic resistant strains of bacteria continue to rise at an alarming rate and they pose a major threat to public health in the view of the World Health Organization. The proprietary, new antimicrobial drug platform at Destiny Pharma, the XF Drug Series, act via an ultra-rapid action which kill bacteria (including antibiotic resistant strains) leaving the bacteria unable to mount a resistance response.
Meet the team
Downing LLP launches 'knowledge intensive' EIS fund to fuel entrepreneurial healthcare businesses in wake of Covid-19
Specialist tax-efficient investment manager Downing LLP is pleased to announce the launch of a new Enterprise ...